Current principles in the screening, diagnosis, and therapy of colorectal cancer

Abstract

The data available in the literature on the prevalence of colorectal cancer (CRC), its risk factors and genetic aspects are analyzed. Basic screening tests and their diagnostic value are described. The paper indicates the importance of methods (colonoscopy, occult blood feces analysis, fecal immunochemical test, determination of molecular genetic profile of fecal enterocytes) for the early primary diagnosis of colonic epithelial tumors and techniques (echography, computed tomography, magnetic resonance imaging, positron emission tomography) that are required to specify clinical TNM staging and enable one to choose an optimal treatment policy for CRC patients owing to the estimation of tumor volume and to the diagnosis of reginal and distant metastases. It also shows that new screening methods based on the detection of molecular markers for early (premorphological) tumor stages are promising. The role of primary CRC prevention aimed at molding and maintaining a healthy lifestyle in the population is demonstrated.

References

  1. Ferlay J, Shin H, Bray F et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No10. Lyon: International Agency for Research on Cancer. 2010;1:118-136.
  2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Stat Database: Incidence-SEER 9 Regs Public Use, Nov. 2011 Sub (1973—2010)-Linked to County Attributes-Total US, 1969—2011 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch; 2013.
  3. Чиссов В.И. и др. Злокачественные новообразования в России в 2010 году: заболеваемость и смертность. ФГБУ МНИОИ им. П.А. Герцена. 2012;1:17-136.
  4. Давыдов М.И., Аксель М.Е. Злокачественные новообразования в России и странах СНГ в 2000 году. М.; 2002.
  5. Ng SC, Wong SH. Colorectal cancer screening in Asia. Br Med Bull. 2013;105:29-42.
  6. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence world wide in 2012. online: http://globocan.iarc.fr/Defaul.aspx
  7. Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2010;24(4):417-125.
  8. Aune D, Lau R, Chan DS, et al. Dairy products and colorectal cancer risk: a systematic review and meta-analysis of cohort studies. Ann Oncol. 2012;23:37-45.
  9. Huxley RR, Ansary-Moghaddam A, Clifton P, Czernichow S, Parr CL, Woodward M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. Int J Cancer. 2009;125:171-180.
  10. Aune D, Lau R, Chan DS et al. Nonlinear reduction in risk for colorectal cancer by fruit and vegetable intake based on meta-analysis of prospective studies. Gastroenterology. 2011;141:106-118.
  11. Белоусова Е.А. Воспалительные заболевания толстой кишки как предраковые заболевания. Российский журнал гастроэнтерологии гепатологии и колопроктологии. 2002;12(4):56-62.
  12. Faivre J, Dancourt V, Lejeune C, Tazi MA, Lamour J, Gerard D et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology. 2004;126:1674-1680.
  13. Steele RJC, Kostourou I, McClements P, Watling C, Libby G, Weller D, Brewster DH, Black R, Carey FA, Fraser C. Effect of repeated invitations on uptake of colorectal cancer screening using faecal occult blood testing; analysis of prevalence and incidence screening. Br Med J. 2010;341:5531. doi: 10.1136/bmj.c5531.
  14. Hubbard RA, Johnson E, Hsia R, Rutter CM. The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2013;22(9):1612-1619. doi: 10.1158/1055-9965.epi-13-0254.
  15. Rabeneck L, Rumble RB, Thompson F, Mills M, Oleschuk C, Whibley A, Messersmith H, Lewis N. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol. 2012;26(3):131-147.
  16. Robertson DJ, Imperiale TF. Stool Testing for Colorectal Cancer. Gastroenterology; Published Online: May 29, 2015
  17. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. N Engl J Med. 2014 Mar 19.
  18. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;(26):2704-2714.
  19. Murata M, Thanan R, Ma N, Kawanishi S. Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotech. 2012;Article ID 623019.
  20. Klampfer L. Cytokines inflammation and colon cancer. Curr Cancer Drug Targets. 2011;11(4):451-464.
  21. Станоевич У., Дехисси Е., Чхиквадзе В. Колоректальный рак при ожирении: патогенетические аспекты. Врач. 2012;8:23-26.
  22. Zlobec I, Bihl M, Schwarb H. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010;127(2):367-380.
  23. Carethers JM. DNA Testing and Molecular Screening for Colon Cancer. Clin Gastroenterol Hepatol. 2014;12(3):377-381. doi: 10.1016/j.cgh.2013.12.007.
  24. Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrat ZD, Oldham-Haltom RL, Fourrier KD, Allawi H, Yab TC, Taylor WR, Simonson JA, Devens M, Heigh RI, Ahlquist DA, Berger BM. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11(10):1313-1318. doi: 10.1016/j.cgh. 2013.04.023.
  25. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology. 2004;126(5):1270-1279.
  26. Richter S. Fecal DNA screening in colorectal cancer. Can J Gastroenterol. 2008;22(7):631-633.
  27. Kisiel JB, et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Alimentary Pharmacol Ther. 2013;37:546.
  28. A Stool DNA Test (Cologuard) for Colorectal Cancer Screening. JAMA. 2014;312(23):2566. doi: 10.1001/jama.2014.15746;
  29. Imperiale TF et al. Multitarget stool DNA testing for colorectal-cancer screening. New Engl J Med. 2014;370:1287.
  30. Mulder SA, Ouwendijk RJ, Giard RW, Van Leerdam ME, Kuipers EJ. Risk analyses for screening sigmoidoscopy based on a colorectal cancer (CRC) population. Scand J Gastroenterol. 2009;44(2):205-210. doi: 10.1080/00365520802433256.
  31. Shroff J, Thosani N, Batra S, Singh H, Guha S. Reduced incidence and mortality from colorectal cancer with flexible-sigmoidoscopy screening: a meta-analysis. World J Gastroenterol. 2014;20(48):18466-184676. doi: 10.3748/wjg.v20.i48.18466.
  32. Hilsden RJ, Rostom A. Colorectal cancer screening using flexible sigmoidoscopy: United Kingdom study demonstrates significant incidence and mortality benefit. Can J Gastroenterol. 2010;24(8): 479-480.
  33. Поддубный Б.К., Кашин С.В., Политое Я.В., Куваев P.O. Колоректальный рак и предопухолевая патология: новые методики эндоскопической диагностики и требования к подготовке толстой кишки. Русcкий медицинский журнал. 2006;8(2):122-124.
  34. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863-1872.
  35. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ. 2014;348. doi: 10.1136/bmj.g2467.
  36. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006;130:1872-1885.
  37. Урядов С.Е. Диагностическая и лечебная эндоскопия в хирургических заболеваниях толстой кишки: Автореф. дис. ... д-ра мед. наук. М.; 2011.
  38. Hawes R. Does virtual colonoscopy have a major role in population- based screening? Gastrointest Endose Clin N Am. 2002;12(1): 85-91.
  39. Johnson C, Chen M, Toledano A. Accuracy of CT colonography for detection of large adenomas and cancer. N Engl J Med. 2008; 359(12):1207-1217.
  40. Pineau BC, Paskett EK, Chen GJ et al. Virtual colonoscopy using oral contrast compared with colonoscopy for the detection of patients with colorectal polyps. Gastroenterology. 2003;125:304-310.
  41. Dominitz J, Robertson D. Colorectal cancer screening with computed tomographic colonography. Gastroenterology. 2009;136(4): 1451-1453.
  42. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer — an example of personalised medicine in action. Cancer Treat Rev. 2013;39:592-601. doi: 10.1016/j.ctrv.2012.12.011.
  43. Heidelberger C, Chaudhuri nk, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179:663-666.
  44. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251-260.
  45. Rasheed ZA, Rubin EH. Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene. 2003;22:7296-7304. doi: 10.1038/sj.onc.1206935.
  46. Jinno H, Tanaka-Kagawa T, Hanioka N, Saeki M, Ishida S, Nishimura T, Ando M, Saito Y, Ozawa S, Sawada J. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos. 2003;31:108-113.
  47. Haaz MC, Rivory L, Riché C, Vernillet L, Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res. 1998;58:468-472.
  48. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237. doi: 10.1200/jco.2004.05.113.
  49. Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS, Etienne-Grimaldi MC, Wei Q. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res. 2011;17:1632-1640. doi: 10.1158/1078-0432.ccr-10-2169.

Statistics

Views

Abstract: 145

PDF (Russian): 91

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2016 Khatkov I.E., Kagramanova A.V., Zakharzhevskaya N.B., Babikova E.A., Generozov E.V., Shcherbakov P.L., Parfenov A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies